Anti-CD19 (Inebilizumab), Humanized Antibody

Anti-CD19 (Inebilizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized afucosylated monoclonal antibody that is directed against CD19. CD19 is a cell surface antigen that is expressed on pre- as well as mature B lymphocytes and is required for proliferation, differentiation, activation of B cells, and antibody production. Although the precise mechanism is not known, it is presumed that the antibody binds to CD19 located on the malignant B cell surface and results in antibody-mediated cellular cytotoxicity. The original drug received approval from the FDA in 2020 to treat neuromyelitis optica spectrum disorder (NMOSD) in patients who were anti-aquaporin 4 (AQP4) positive

Immunogen Sequence:Human CD19

Target Alternative Name:MEDI-551, MEDI 551, MEDI551, B4, CVID3,CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen

Species Reactivities:Human

Tag Line:The biosimilar is a humanized afucosylated monoclonal antibody that specifically targets CD19 and causes antibody-dependent cellular cytolysis

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.